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Summary
Background: Leucopenia is a common side effect in patients treated with thiopuri-
nes. Variants in the thiopurine S-methyltransferase (TPMT) gene are the best-known
risk factor, but only explain up to 25% of leucopenia cases.
Aim: To identify the clinical risk factors for thiopurine-induced leucopenia in
patients without a common TPMT variant, and explore if these patients are at
increased risk for infections.
Methods: Post hoc analysis of the Thiopurine response Optimisation by Pharmaco-
genetic testing in Inflammatory bowel disease Clinics (TOPIC) trial. For this analysis,
patients without a variant in TPMT (*2, *3A or*3C) were included. Uni- and multivari-
ate Cox-proportional hazard models were used to identify risk factors for leucopenia
and infections. Leucopenia was defined as a white blood cell (WBC) count
<3.0 9 109/L and infections were classified according to the Common Terminology
Criteria for Adverse Events.
Results: Sixty hundred and ninety-five patients (90.6%) included in the TOPIC-trial
had no variant in TPMT, of which 45 (6.5%) developed leucopenia. Median time to
leucopenia was 56 (29-112) days. Multivariate analysis showed that use of mercap-
topurine compared to azathioprine was associated with leucopenia (hazard ratio
[HR] 2.61 [95% CIs, 1.39-4.88; P < .01]) and a higher baseline WBC count was pro-
tective (HR 0.80 [95% CIs, 0.71-0.89; P < .01]). Risk factors for infections were
older age (per 10 year; HR 2.07 [95% CIs, 1.18-3.63; P = .01]) and concomitant use
of biologic drugs (HR 2.15 [95% CIs, 1.14-4.07; P = .02]).
Conclusions: Low baseline WBC count and mercaptopurine, due to a relatively higher
dose, were risk factors for thiopurine-induced leucopenia in patients without a TPMT
variant.
The Handling Editor for this article was Professor Ailsa Hart, and it was accepted for publication after full peer-review.
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1 | INTRODUCTION
Thiopurines are immunosuppressive drugs that have an important
role in the treatment of inflammatory bowel diseases (IBD), both as
monotherapy and as combination treatment with biologics.1-3 Yet
many patients have to discontinue treatment in an early phase due
to ineffectiveness or side effects. Leucopenia as a result of thiop-
urine use is a frequent reason for dose reductions and/or (tempo-
rary) treatment discontinuation in patients with IBD, leading to
suboptimal treatment conditions.4,5 Dose reductions or treatment
discontinuation in case of leucopenia is mainly driven by fear for
infectious complications.4
The best-known risk factor for the development of thiopurine-
induced leucopenia is the presence of genetic variants in the thiop-
urine S-methyltransferase (TPMT) gene, which leads to a reduced or
negligible TPMT activity and subsequently to excessive cytotoxic
6-thioguanine nucleotide (6-TGN) metabolite formation.6,7 In the
Caucasian population, 95% of the decreased TPMT enzyme activity
follows from three common variants (TPMT*2, TPMT*3A or
TPMT*3C).7 Especially patients with a homozygous genetic variant in
TPMT (~0.3% of the population), and to a lesser degree patients with
a heterozygous variant in TPMT (~10% of the population) are at
increased risk for severe, life-threatening, myelosuppression when
treated with the standard recommended dose of azathioprine (AZA)
or mercaptopurine (MP).8-10 Leucopenia can be prevented by geno-
typing for these variants prior to initiation of thiopurine treatment
and subsequently taper the thiopurine dose to 50% of the original
dose in those heterozygous for a variant in TPMT and 0%-10% of
the original dose in patients with a homozygous variant.11-13 How-
ever, only up to 25% of the leucopenia cases can be explained by
variants in TPMT, which makes that leucopenia is frequently
observed in patients without a TPMT variant.1,5,14-16 This suggests
that also other genes and environmental or clinical factors may con-
tribute to the risk of leucopenia during thiopurine treatment.17-21
It is unknown to what degree leucopenia attributes to the risk for
infections. Recent studies in the treatment of hepatitis C did not reveal
a relation between interferon-induced leucopenia and infectious com-
plications. 22,23 If this also applies for thiopurine treatment in IBD,
strict dose reductions in case of leucopenia might be redundant.
In the present post hoc analysis of the “Thiopurine response
Optimisation by Pharmacogenetic testing in Inflammatory bowel
disease Clinics” (TOPIC) trial, we aimed to (1) identify clinical risk
factors for the development of TPMT-independent leucopenia in
patients with IBD treated with thiopurines and (2) evaluate whether
TPMT-independent leucopenia is a risk factor for the occurrence of
infections in these patients.
2 | METHODS
2.1 | Patients
We designed a case-control study with patient data from the TOPIC
trial, which evaluated the efficacy of pre-treatment TPMT genotyping
on the occurrence of myelosuppression during thiopurine treat-
ment.14 In brief, in the TOPIC trial thiopurine-naive patients with
IBD with an indication for thiopurine treatment (indicated by the
treating physician) were randomised 1:1 for the intervention group
with prior to treatment genotyping of the three most common
genetic variants (*2, *3A and *3C) in TPMT vs the standard of care
group with thiopurine dosing according to current standard of care;
AZA (2.0-2.5 mg/kg) and MP (1.0-1.5 mg/kg). In patients allocated
to the intervention arm, a 50% dose reduction was recommended in
case of a heterozygous TPMT variant and in case of a homozygous
TPMT variant 10% of the standard dose or an alternative treatment
was advised. Patients were followed for 20  6 weeks with labora-
tory measurements including white blood cell (WBC) count at week
0, 1, 2, 4, 6, 8, 20 and when indicated by the treating physician.
Neutrophil count was not routinely measured in the TOPIC trial.
Physicians were free in their choice for AZA or MP and were
advised to start full dose. After the follow-up period, TPMT-genotype
was assessed in patients randomised to the standard of care arm
and in addition TPMT activity was assessed in all patients. Main
exclusion criteria of the TOPIC trial were previous use of thiopuri-
nes, co-treatment with allopurinol, baseline WBC count <3.0 9 109/L,
baseline liver test abnormalities (alanine transaminase, aspartate
transaminase, alkaline phosphatase and/or gamma glutamate
transpeptidase ≥ two times the normal upper limit), known TPMT
enzyme activity or TPMT-genotype. 6-Methylmercaptopurine ribonu-
cleotides (6-MMPR) and 6-TGN levels were assessed at week eight
in the first 301 patients included in the trial. For a detailed descrip-
tion of the study design, patient selection and patient data, we refer
to Coenen et al14 The TOPIC trial was approved by the institutional
ethics committee and all patients provided written informed consent
(clinicaltrials.gov, NCT00521950).
The primary aim of the current study was to indentify risk fac-
tors for leucopenia in patients without one of the tested genetic
variants in TPMT. All randomised patients who started with a thiop-
urine and tested negative for a variant in TPMT were included in an
intention-to-treat analysis (Figure 1). Patients allocated to the geno-
typing arm with a TPMT variant (treated with 50% of the regular
dose), as well as patients assigned to the standard of care arm with
a TPMT variant (treated with 100% of the regular dose) were
excluded. The Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0 was used to classify the severity of leucope-
nia.24 According to these criteria, mild leucopenia (grade 1) is defined
as a WBC count between the lower limit of normal and ≥3.0 9 109/L,
moderate leucopenia (grade 2) was defined as a WBC count between
≥2.0 9 109/L and <3.0 9 109/L and severe leucopenia (grade 3) if the
WBC count was <2.0 9 109/L. For the current analysis, only cases of
moderate and severe leucopenia were included. Leucopenia which
developed 2 weeks or later after discontinuation of the thiopurine
was not considered to be associated with thiopurine use.
The second goal of this study was to explore if patients with
TPMT-independent leucopenia during thiopurine treatment were at
increased risk for infections. For this analysis, infections were classi-
fied according to the CTCAE.24 The source of infection was reported
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and severity was subdivided in grade 1-5, in which grade 1 means
no indication for infection treatment, grade 2: oral intervention
(antibiotics, antifungal or anti-viral) treatment indicated, grade 3:
intravenous treatment (antibiotics, antifungal or anti-viral) or opera-
tive intervention indicated, grade 4: life-threatening consequences
and grade 5 indicates death from the infection. Only clinical relevant
infections, grade 2 or higher, were included in the analysis, ie, infec-
tions for which oral or intravenous antibiotic, antifungal or anti-viral
treatment was indicated. Infections up to 2 weeks after thiopurine
treatment discontinuation were included. Infections were classified
as ‘leucopenia-associated infection’ when the infection occurred
while the patient was leucopenic (WBC count <3.0 9 109/L) or
within 2 weeks after the leucopenia was resolved.
Covariates included in the analysis were baseline (week 0)
WBC count and week one decrease in WBC count, defined as
the decrease in WBC level after 7 (1) days of thiopurine use.
Furthermore, use of concomitant drugs, ie, use of 5-aminosalicylic
acid (5-ASA), steroids, biologics and ACE-inhibitors at baseline or
initiated during the use of the initial thiopurine was reported.
Steroids with limited systemic bioavailability, such as budesonide
were not included. Information about co-morbidities (diabetes mel-
litus, chronic pulmonary disease and rheumatoid diseases) was
reported. Patients were classified as active smoker or nonsmoker,
determined at baseline. Disease severity at baseline was classified
according to the Harvey-Bradshaw Index in patients with Crohn’s
disease (CD) and partial Mayo score for ulcerative colitis (UC).
AZA dose in mg/kg was divided by 2.08 for comparison with MP
dose.12,25
2.2 | TPMT enzyme activity and TPMT genotyping
TPMT enzyme activity was measured in red blood cells (RBCs) using a
high-performance liquid chromatography method described previ-
ously.14 Genotyping of variants *2, *3A and *3C in TPMT was described
previously.14 Possible cases of TPMT-induced leucopenia caused by
rare variants, other than *2, *3A and *3C in TPMT, might have been
missed. For this reason, we sequenced all exons including splice sites
in the TPMT gene in patients with a low TPMT activity (<60 mg
6-methylguanine/mmolHb.h) or who developed leucopenia (WBC
<3.0 9 109/L). Polymerase chain reaction was performed on 10 ng
DNA using AmpliTaq Gold 360 mastermix (Life Techologies, Bleiswijk,
The Netherlands). Primers are described elsewhere.14 Annealing tem-
perature was 56°C for all exons. PCR products were purified using
Multiscreen filter plates (Millipore Carrigtwohill, Cork, Ireland). Purified
products were used for Sanger sequence analysis (bidirectional) with
dye-termination chemistry (BigDye Terminator, version 3) on a 3730
DNA analyser (Applied Biosystems, Inc., Foster City, CA, USA.
2.3 | 6-MMPR and 6-TGN metabolite
measurements
By protocol, 6-TGN and 6-MMPR levels at week eight were
assessed at a routine check-up in the first 301 patients included in
the TOPIC trial. 6-TGN and 6-MMPR levels were determined in
RBCs by high-performance liquid chromatography according to the
Lennard method.14 Median (IQR) thiopurine metabolite concentra-
tions are presented in pmol/8x108RBCs.
Patients included in the
TOPIC trial
Standard of care arm (n = 369)
TPMT (*2, *3A, *3C) analysed afterwards
Heterozygote TPMT variant (n = 34)
AZA (2.0-2.5 mg/kg) or MP (1.0-1.5 mg/kg)
No TPMT variant (n = 695)
AZA (2.0-2.5 mg/kg) or MP (1.0-1.5 mg/kg)
Included in this post hoc analysis
Heterozygote TPMT variant (n = 38)
AZA (1.0-1.25 mg/kg) or MP (0.5-0.75 mg/kg)
Homozygote TPMT variant (n = 1)
Alternative treatment started
Pre-treatment genotyping of *2, *3A and
*3C in TPMT (n = 399)
Heterozygote variant: 50% dose reduction
Homozygote variant: 0-10% of orignial dose
F IGURE 1 Flowchart of patient selection for this post hoc analysis. All patients who participated in the TOPIC trial, without a genetic
variant in TPMT, were included. AZA, azathioprine; MP, mercaptopurine; TPMT; thiopurine S-methyltransferase
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2.4 | Statistical analysis
All analyses were performed using SPSS version 20.0.0.1 (SPSS Inc.,
Chicago, IL, USA). First, leucopenia rate was calculated for patients
without one of the tested TPMT variants. Characteristics of patients
with and without TPMT-independent leucopenia were compared by
Chi-squared test (categorical data) or independent t test (continuous
data). Nonparametric tests were used when data were not dis-
tributed normally. In a similar fashion, characteristics of patients with
and without an infection during the use of the initial thiopurine were
analysed. In patients with steady-state metabolite levels at week 8,
the 6-MMPR, the 6-TGN levels and the 6-MMPR/6-TGN ratio were
compared by Mann-Whitney U test in patients with and without
TPMT-independent leucopenia.
Univariate Cox-proportional hazard models were used to identify
clinical factors associated with the development of leucopenia in
patients without one of the tested TPMT variants. The time to
leucopenia and in patients without leucopenia the number of days
of thiopurine use served as reference. Variables with a P < .2 were
included in a multivariate Cox-proportional hazard model with back-
ward elimination to explore which factors were independently asso-
ciated with the development of TPMT-independent leucopenia
during thiopurine treatment. In the same way, uni- and multivariate
Cox-proportional analysis was performed to identify factors associ-
ated with the occurrence of infections during thiopurine treatment.
The variable leucopenia was retained in this model, since we wanted
to explore whether these patients were at increased risk for infec-
tions. A P < .05 was considered as statistically significant.
3 | RESULTS
3.1 | Patients
Of the 796 patients with IBD randomised in the TOPIC trial, 29
patients were excluded because they did not start with a thiopurine
or were lost to follow-up. Of the remaining 767 patients who actu-
ally started with thiopurine treatment, 72 (9.4%) carried a genetic
variant in TPMT and were excluded, which leaves 695 patients with
IBD for this analysis (Figure 1). Of the 695 included patients, 247
patients (35.5%) were treated with MP (mean dose  SD
1.20  0.15 mg/kg) and 448 patients (64.5%) were treated with
AZA (mean dose  SD 2.19  0.20 mg/kg). To compare the AZA
dose with the MP dose, a conversion rate of 2.08 was applied,
resulting in a mean converted dose of 1.05  0.09 mg/kg. T test
showed that the difference was significant (P < .001).
3.2 | Leucopenia
Of the 695 patients without a variant in TPMT, 45 (6.5%) developed
leucopenia in the first 5 months of treatment; 41 (5.9%) patients
developed moderate leucopenia and four (0.6%) patients developed
severe leucopenia. See Table S1 for detailed information of the 45
patients with TPMT-independent leucopenia. Median time (IQR) to
onset of leucopenia was 56 (29-112) days. In 11 patients (24.4%)
with TPMT-independent leucopenia the thiopurine treatment was
discontinued, while in 20 patients (44.5%) the thiopurine dose was
reduced, in 12 patients (26.7%) leucopenia recovered without an
intervention and in two patients (4.4%) the intervention was
unknown. TPMT enzyme activity mean (SD) was not different
between patients with and without leucopenia (95.8  21.8 vs
94.4  18.8 mg/mmol Hb.h, P = .65; Figure 2).
Table 1 shows the characteristics of patients with and without
TPMT-independent leucopenia during thiopurine treatment. Table 2
provides the results of the uni- and multivariate Cox-proportional
hazard model and shows that the choice for MP compared to AZA,
Hazard ratio (HR) 2.61 (95% CIs 1.39-4.88; P < .01) was an indepen-
dent risk factor for TPMT-independent thiopurine-induced leucope-
nia. Furthermore, a higher baseline WBC count protected the patient
from TPMT-independent thiopurine-induced leucopenia, HR 0.80
(95% CIs 0.71-0.89; P < .01): for every increase of WBC at baseline
with 1.0 9 109/L the risk of leucopenia decreased with 0.80.
In 17 patients who developed leucopenia after 8 weeks, steady-
state 6-MMPR and 6-TGN levels were assessed. Neither 6-TGN
levels, nor 6-MMPR levels, nor the 6-MMPR/6-TGN ratio were dif-
ferent from patients without leucopenia in whom steady-state week
eight levels were assessed; 267 (205-364) pmol/8 9 108 RBCs vs
242 (186-341) pmol/8 9 108 RBCs, P = .39 and 3596 (1304-
12 824) pmol/89108 RBCs vs 3600 (1326-7415) pmol/8 9 108
RBCs, P = .63. The 6-MMPR/6-TGN median (IQR) ratio was 13 (6-
35) in patients with leucopenia and 14 (6-32) in patients without
leucopenia, P = .80.
3.3 | Infections
Sixty-five (9.4%) of the 695 patients developed an infection while
being treated with a thiopurine during the study period of 5 months.
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F IGURE 2 Thiopurine S-methyltransferase (TPMT) activity in
patients with and without TPMT-independent thiopurine-induced
leucopenia. Leucopenia was defined as white blood cell count of
<3.0 9 109/L
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Fifty-nine (8.5%) infections were classified as grade 2 or higher
according to the CTCAE, of these, 32 patients had a grade 2 infec-
tion, 25 patients a grade 3 infection and 2 patients were classified
as grade 4 infection. Two patients died during the TOPIC trial, both
were excluded from this analysis, one patient had a heterozygous
TPMT variant and the other patient developed an infection while he
was treated with steroids, infliximab and methotrexate, more than
2 weeks after thiopurine treatment was discontinued.14 Median
(IQR) time after the start of thiopurine treatment to an infection
grade 2 or higher was 54 (18-88) days. Of the 45 patients with
TPMT-independent leucopenia five patients (11.1%), of whom three
had a severe leucopenia (WBC count <2.0 9 109/L), experienced a
“leucopenia-associated infection”, while the infection rate in patients
without leucopenia was 54 in 650 patients (8.3%) (P = .41). Details
about infection localisations are depicted in Table 3. Characteristics
of patients with and without an infection are presented in Table 4.
In the multivariate Cox-proportional hazard model only age (per
10 years), HR 2.07 (95% CIs, 1.18-3.63; P = .01) and concomitant
use of biologic drugs, HR 2.15 (95% CIs, 1.14-4.07; P = .02), were
associated with the occurrence of infections (Table 5).
4 | DISCUSSION
In this study, we showed that in patients with IBD without a variant
in TPMT, baseline WBC count and the choice of MP compared to
AZA, were independent risk factors for thiopurine-induced leucope-
nia during the first five months of treatment. However, this did not
result in a higher risk for infections. Infections during thiopurine
treatment were more frequently seen in elderly and in patients with
concomitant use of biologic drugs.
The overall incidence of thiopurine-induced leucopenia is esti-
mated to be 7%.4 Importantly, in 75% of the patients this is not cor-
related with a genetic variant in TPMT. As shown in this study,
leucopenia still occurs in 6.5% of the patients without a genetic vari-
ant in TPMT, often leading to dose reductions or treatment discon-
tinuation.5 Thiopurine-induced leucopenia is at least partially dose-
dependent.26 In a previous analysis of all patients included in the
TOPIC trial, we already showed that patients treated with MP were
relatively higher dosed than patients treated with AZA and that this
resulted in amongst others a higher rate of leucopenia.25 This differ-
ence annulled in a secondary analysis with adjustment for dose and
metabolite levels, therefore an interdrug difference between AZA
and MP seems unlikely. Also, other studies showed a relatively
higher dose and leucopenia rate in patients on MP compared to
AZA.20,21,27 The difference might be attributed to the absence of
MP tablets with a content of 25 mg, which allow a more person-
alised dosing. Another explanation might be derived from the con-
version rate of 2.08, which is used to calculate the MP dose from
the AZA dose. This conversion rate includes assumptions such as a
100% bioavailability.28 The higher rate of dose-dependent side
effects might be prevented with a slight reduction of the MP starting
dose.25
In our study, 6-TGN and 6-MMPR metabolite levels were not
increased in patients with leucopenia. It must be stressed that most
patients with leucopenia were subjected to dose reductions or treat-
ment discontinuation before week eight. Therefore, steady-state
week eight 6-TGN levels were available only in a limited number of
cases, which most likely explains why we found no difference.
Besides 6-TGN levels, also excessively elevated 6-MMPR levels have
been associated with leucopenia.21 The increased risk for leucopenia
with a lower baseline WBC count has also been reported in the
TABLE 1 Characteristics of the patients with and without TPMT-
independent thiopurine-induced leucopenia
Characteristics
Leucopenia
P-valueYes (n = 45) No (n = 650)
Male sex, n (%) 21 (47) 289 (45) .77
Age, y, median (IQR) 43 (28-51) 40 (26-53) .52
BMI, mean (SD) 24.9 (5.6) 24.8 (4.8) .89
Current smoker, n (%) 4 (9) 156 (24) .02
Drug, AZA, n (%) 18 (40) 430 (66) <.01
Thiopurine dose (mg/kg),
median (IQR)a
1.15 (1.03-1.31) 1.09 (1.02-1.17) .03
TPMT activity, mg/mmol
Hb.h, mean (SD)
95.8 (21.7) 94.4 (18.8) .65
Disease, CD, n (%)b 24 (53) 399 (61) .33
Wk 0 WBC count,
109/L, mean(SD)
8.4 (3.5) 10.6 (3.6) <.01
Wk 1 decrease
WBC count,
109/L, mean (SD)c
1.2 (2.9) 0.8 (2.8) .42
Concomitant drugs, n (%)
5-Aminosalicylic acid 25 (56) 320 (49) .41
Systemic steroids 27 (60) 371 (57) .74
Biologics 9 (20) 66 (10) .04
ACE-inhibitor 2 (4) 20 (3) .61
Co-morbidity, n (%)d
Diabetes mellitus 3 (7) 22 (3) .25
Rheumatic disease 2 (5) 36 (6) .75
Asthma/COPD 3 (8) 66 (12) .45
Disease severity
CD, HBI, mean (SD)e 3.7 (3.6) 3.6 (3.1) .83
UC, partial Mayo,
mean (SD)f
3.7 (1.5) 3.8 (1.7) .83
Leucopenia was defined as a white blood cell count (WBC) of
<3.0 9 109/L.
AZA, azathioprine; BMI, body mass index; CD, Crohn’s disease; HBI; Har-
vey-Bradshaw Index; TPMT, thiopurine S-methyltransferase; UC, ulcera-
tive colitis; WBC, white blood cell.
aAZA dose in mg/kg was divided by 2.08 to compare with MP dosage.
bSeven patients were diagnosed with indeterminate colitis.
cKnown for 492 patients.
dKnown for 602 patients.
eKnown for 325 patients with CD.
fKnown for 225 patients with UC.
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setting of ganciclovir- and chemotherapy-induced leucopenia.29,30 In
contrast to a previous study, we did not find a correlation between
concomitant 5-ASA use and myelosuppression.31 It has been sug-
gested that 5-ASA might increase 6-TGN levels by a weak inhibition
of the TPMT enzyme activity and therefore may increase the risk of
myelosuppression.32 Previous studies using data of the TOPIC trial
already showed that 6-TGN levels were not significantly higher in
patients on 5-ASA, which explains why we found no increased
leucopenia rate in this group.33,34 It is known that smoking leads to
an increase of WBC count of 0.5–1.0 9 109/L as a result of a low-
grade systemic inflammation.35 Indeed, in our study univariate analy-
sis showed that smokers had less often leucopenia, however, this
did not reach significance in the multivariate analysis.
Pharmacogenetic testing of TPMT is a cost-effective strategy to
prevent severe, life-threatening, myelosuppression, in those who are
TPMT-deficient.36,37 This strategy is strongly recommended by sev-
eral guidelines.9,11,38,39 TPMT-related and TPMT-independent leuco-
penia may be considered as two separate entities. Most studies
reporting on thiopurine-induced leucopenia provide no information
regarding the TPMT status, which hampers extrapolation to daily
clinical practice.40-42 For this reason, we specifically focused on the
patients without a variant in TPMT. Thiopurine-induced leucopenia in
patients without genetic variants in TPMT occurred at any moment
during the first 5 months of therapy, with a slight peak in the first
2 months. Therefore, the current routine laboratory tests should
remain mandatory to identify patients with myelosuppression in an
early stage.1 In more than 90% of the cases leucocyte levels did not
drop below 2.0 9 109/L. Yet thiopurine dosage was reduced or
treatment was discontinued in two-thirds of these patients, probably
due to fear for infectious complications. Overall, most cases of
TPMT-independent leucopenia are mild and therefore did not require
immediate treatment discontinuation or dose reduction. However in
the setting of an unknown TPMT-genotype, all cases of leucopenia
in the first months of thiopurine treatment should be considered as
potentially TPMT-induced, because otherwise life-threatening myelo-
suppression might occur in the patients whom actually have a
genetic variant in TPMT.1 Previous studies estimated a cumulative
infection rate of 6.5% among patients with thiopurine-induced leuco-
penia.4 In the present study, we showed that infection rates are
comparable for patients with and without TPMT-independent leuco-
penia. Both viral and bacterial infections were seen, however in most
of the cases no specific pathogen was isolated. The risk for bacterial
infections increases with neutrophil levels below 0.5 9 109/L. 43
These levels are often observed in patients with a homozygous vari-
ant in TPMT when treated with standard thiopurine doses due to the
very high 6-TGN levels.1,44 In our study, neutrophil levels at time of
leucopenia were available in ~50% of the patients and a neutrophil
count below 0.5 9 109/L was observed in only one patient, which
suggests that severe neutropenia is not frequently observed in
patients without a TPMT variant. This, in combination with the fact
that in most cases leucopenia was only moderate (WBC count
≥2.0 9 109/L), might explain why we did not find a higher infection
rate in patients with a thiopurine-induced leucopenia. It must be
mentioned that in 69% of patients with leucopenia the thiopurine
dose was reduced or treatment was discontinued. It cannot be
excluded that this prevented the aggravation of the leucopenia and/
or the development of infectious complications, which is an impor-
tant limitation of our study. Yet, our findings corroborate studies
exploring the risk of infections in hepatitis C treatment. In these
studies, interferon-induced leucopenia was not a risk factor for
infectious complications.22,23 The lack of association between leuco-
penia and infections might have great implications for clinical prac-
tice. Some studies showed a relation between mild leucopenia
(defined as WBC count ≥3.0 and <5.0 9 109/L) and treatment effi-
cacy.45,46 This increased treatment efficacy in case of leucopenia
TABLE 2 Uni- and multivariate Cox-proportional hazards regression analysis to explore factors associated with development of thiopurine-
induced leucopenia in the first five months of thiopurine treatment in patients without a TPMT variant
Univariate analysis Multivariate analysis
Hazard ratio (95% CIs) P-value Hazard ratio (95% CIs) P-value
Drug type, MP vs AZA 2.45 (1.35-4.48) .003 2.61 (1.39-4.88) .003
Week 0 WBC count, 109/L 0.78 (0.70-0.88) <.001 0.80 (0.71-0.89) <.001
Concomitant biologic drugs 1.67 (0.80-3.49) .17
Thiopurine dosage (mg/kg) 5.59 (0.68-46.1) .11
Active smoking 0.37 (0.13-1.03) .06
AZA dose in mg/kg was divided by 2.08 to compare with MP dosage.
AZA, azathioprine; MP, mercaptopurine; WBC, white blood cell.
TABLE 3 Infection localisation according to the common
terminology criteria for adverse events (version 4.0). Only patients
with infections grade 2 or higher were included
Localisation Frequency
Lung infection 16
Urinary tract infection 8
Skin infection 7
Abdominal infection 5
Infectious enterocolitis 4
Upper respiratory infection 2
Meningitis 1
Unknown 16
Overall 59
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was independent from 6-TGN levels.45 Therefore, if our observations
are correct, a more preserved strategy in case of moderate leucope-
nia would not increase infection risk, prevents a patient from under-
dosing, and possibly increases treatment efficacy. Future studies are
needed to evaluate whether such a strategy is safe and does
increase the infection rate or lead to more patients with severe
leucopenia.
Age and concomitant use of biologics were the only factors asso-
ciated with the occurrence of infections. Increasing age is a known
risk factor for infections, which is thought to result from an impaired
immune response in the elderly.47,48 This has also been reported in
patients with IBD.49,50 In contrast to many clinical trials, there was
no upper age limit with inclusion in the TOPIC trial. As a conse-
quence, 105 (15.1%) of the patients included in current study were
60 years or older, of whom 24 patients were 70 years or older. This
makes it a representative sample for the real life setting in the era of
an ageing IBD population.51 The higher risk for infections with con-
comitant use of biologic drugs is not unexpected, since use of bio-
logics is an independent risk factor for (opportunistic) infections.49,52
This observation is not limited to IBD, but is also observed in other
immune-mediated diseases.53,54 In contrast to previous studies, we
found no relation with concomitant steroid use.49 A likely explana-
tion is that steroid use was not protocolised and as a consequence
the group of patients on oral steroids was very heterozygous and
TABLE 4 Characteristics of the patients with and without an infection during thiopurine treatment
Characteristics
Infection during thiopurine treatment
P-valueYes (n = 59) No (n = 636)
Male sex, n (%) 21 (36) 289 (45) .15
Age,y, median (IQR) 42 (33-60) 40 (26-53) .11
BMI, mean (SD) 24.9 (6.1) 24.7 (4.7) .82
Current smoker, n (%) 18 (31) 142 (22) .16
Drug, AZA, n (%) 42 (71) 406 (64) .26
Thiopurine dose in mg/kg, median (IQR)a 1.08 (1.02-1.16) 1.10 (1.02-1.19) .50
TPMT activity, mg/mmol Hb.h, mean (SD) 96.2 (19.6) 94.4 (18.9) .47
Disease, CD, n (%)b 38 (64) 385 (61) .63
Wk 0 WBC count, 109/L, mean (SD) 9.9 (3.5) 10.5 (3.6) .21
Wk 1 decrease WBC count, 109/L, mean (SD)c 0.4 (3.0) 0.9 (2.8) .29
Leucopenia 5 (9)g 37 (6) .41
Concomitant drugs, n (%)
5-Aminosalicylic acid 28 (48) 317 (50) .47
Systemic steroids 33 (56) 632 (58) .79
Biologics 12 (20) 63 (10) .01
ACE-inhibitor 2 (4) 20 (3) .61
Co-morbidity, n (%)d
Diabetes mellitus 1 (2) 24 (4) .41
Rheumatic disease 8 (16) 61 (11) .32
Asthma/COPD 5 (10) 33 (6) .28
Disease severity
CD, HBI, mean (SD)e 3.7 (2.8) 3.6 (3.1) .80
UC, partial Mayo, mean (SD)f 3.9 (1.7) 3.8 (1.7) .82
Leucopenia was defined as a WBC count of <3.0 9 109/L. Only infections grade 2 or higher according to the Common Terminology Criteria for Adverse
Events were included.
AZA, azathioprine; BMI, body mass index; CD, Crohn’s disease; HBI; Harvey-Bradshaw Index; TPMT, thiopurine S-methyltransferase; UC, ulcerative coli-
tis; WBC, white blood cell.
aAZA dose in mg/kg was divided by 2.08 to compare with MP dosage.
bSeven patients were diagnosed with indeterminate colitis.
cKnown for 492 patients.
dKnown for 602 patients.
eKnown for 325 patients with CD.
fKnown for 225 patients with UC.
gAs follows from Table 3, 45 patients experienced leucopenia, however in 3 patients with leucopenia during thiopurine treatment who also had an infec-
tion, the infection was not considered to be related to leucopenia, either because leucopenia was already resolved for more than 2 weeks (2 patients),
or the infection was already known before the leucopenia occurred (1 patient). For the analysis, these cases were counted as an infection without
leucopenia.
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included patients on low maintenance dose, short-term use during
thiopurine initiation, but also patients on a high dose for a longer
period. Furthermore, patients currently taking no steroids still have
an increased infection risk, when treated with steroids in the past
2 years.55 We found no association between diabetes mellitus or
smoking and infection risk, probably because of the relatively small
study size and short follow-up period.56,57
This study comes with some limitations. First, current analyses
were not included in the original study protocol. Second, patients in
the TOPIC trial were only tested for the three common variants in
TPMT (*2, *3A and *3C), which cover more than 90% of the preva-
lence of genetic variants in TPMT in Caucasians. Therefore, it is pos-
sible that we missed some patients with other TPMT variants.58 This
was circumvented by sequencing the coding region of TPMT in all
patients with a low TPMT activity or those who developed leucope-
nia; which did not reveal other variants (unpublished data).
Furthermore, we assumed that when the treating physician started
anti-infectious therapy there was a true suspicion of an infection.
This comes with some restrictions, since exacerbations of IBD or flu-
like side effects (which might include elevation of C-reactive protein)
can mimic (gastro-intestinal) infections leading to the prescription of
antibiotics. Finally, (viral) infections may induce leucopenia.19
However, if this is the case it would have resulted in an overestima-
tion of ‘leucopenia-associated infections’ and further bolster our
findings that (moderate) leucopenia itself is not a risk factor for
infectious complications.
In conclusion, in the present study we showed that the choice
for MP compared to AZA (as a result of a relatively higher dose)
and baseline WBC count are risk factors for the development of
thiopurine-induced leucopenia in patients without a genetic variant
in TPMT; however, this was not associated with an increased risk
for infections. Multivariate analysis showed that older patients and
patients with concomitant use of biologics had a higher risk for
infections during thiopurine treatment and should therefore be
treated with more caution. Our data suggest that moderate TPMT-
independent leucopenia during thiopurine treatment might be
accepted in the light of close monitoring of WBC count and
metabolite levels.
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